Loading...

Genomic Vision Société Anonyme

DB:G09
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
G09
DB
€5M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The last earnings update was 43 days ago. More info.


Add to Portfolio Compare Print
  • Genomic Vision Société Anonyme has significant price volatility in the past 3 months.
G09 Share Price and Events
7 Day Returns
-4%
DB:G09
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-87.7%
DB:G09
-9.2%
DE Biotechs
-6.7%
DE Market
G09 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Genomic Vision Société Anonyme (G09) -4% -5.4% -2.4% -87.7% -97.2% -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • G09 underperformed the Biotechs industry which returned -9.2% over the past year.
  • G09 underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
G09
Industry
5yr Volatility vs Market

G09 Value

 Is Genomic Vision Société Anonyme undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Genomic Vision Société Anonyme. This is due to cash flow or dividend data being unavailable. The share price is €0.243.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Genomic Vision Société Anonyme's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Genomic Vision Société Anonyme's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:G09 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in EUR €-1.21
ENXTPA:GV Share Price ** ENXTPA (2019-04-18) in EUR €0.3
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Genomic Vision Société Anonyme.

DB:G09 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:GV Share Price ÷ EPS (both in EUR)

= 0.3 ÷ -1.21

-0.25x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genomic Vision Société Anonyme is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Genomic Vision Société Anonyme is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Genomic Vision Société Anonyme's expected growth come at a high price?
Raw Data
DB:G09 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.25x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
33.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Genomic Vision Société Anonyme, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Genomic Vision Société Anonyme's assets?
Raw Data
DB:G09 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in EUR €0.52
ENXTPA:GV Share Price * ENXTPA (2019-04-18) in EUR €0.3
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:G09 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:GV Share Price ÷ Book Value per Share (both in EUR)

= 0.3 ÷ 0.52

0.58x

* Primary Listing of Genomic Vision Société Anonyme.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genomic Vision Société Anonyme is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Genomic Vision Société Anonyme's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Genomic Vision Société Anonyme has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

G09 Future Performance

 How is Genomic Vision Société Anonyme expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
33.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Genomic Vision Société Anonyme expected to grow at an attractive rate?
  • Unable to compare Genomic Vision Société Anonyme's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Genomic Vision Société Anonyme's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Genomic Vision Société Anonyme's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:G09 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:G09 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 33.3%
DB:G09 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 68.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:G09 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:G09 Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 9 -2 -3 1
2019-12-31 4 -6 -7 1
DB:G09 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-12-31 2 -7
2018-09-30 3 -7
2018-06-30 4 -6 -7
2018-03-31 4 -7 -8
2017-12-31 4 -8 -9
2017-09-30 4 -10
2017-06-30 4 -10 -10
2017-03-31 3 -9 -9
2016-12-31 3 -8 -9
2016-09-30 4 -7
2016-06-30 4 -6 -6
2016-03-31 4 -6 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Genomic Vision Société Anonyme is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Genomic Vision Société Anonyme's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:G09 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Genomic Vision Société Anonyme Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:G09 Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -0.19 -0.19 -0.19 1.00
2019-12-31 -0.43 -0.43 -0.43 1.00
DB:G09 Past Financials Data
Date (Data in EUR Millions) EPS *
2018-12-31
2018-09-30
2018-06-30 -1.21
2018-03-31 -1.50
2017-12-31 -1.83
2017-09-30 -2.03
2017-06-30 -2.23
2017-03-31 -2.08
2016-12-31 -1.93
2016-09-30 -1.65
2016-06-30 -1.37
2016-03-31 -1.17

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Genomic Vision Société Anonyme will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Genomic Vision Société Anonyme's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Genomic Vision Société Anonyme has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

G09 Past Performance

  How has Genomic Vision Société Anonyme performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Genomic Vision Société Anonyme's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Genomic Vision Société Anonyme does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Genomic Vision Société Anonyme's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Genomic Vision Société Anonyme's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Genomic Vision Société Anonyme's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Genomic Vision Société Anonyme Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:G09 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2.38 -6.90 0.11
2018-09-30 2.96 -6.89 2.91 1.73
2018-06-30 3.54 -6.89 5.55 3.64
2018-03-31 3.54 -7.98 5.80 4.01
2017-12-31 3.55 -9.07 6.06 4.38
2017-09-30 3.55 -9.61 6.20 4.85
2017-06-30 3.55 -10.15 6.18 5.48
2017-03-31 3.43 -9.38 5.70 5.65
2016-12-31 3.31 -8.61 5.23 5.83
2016-09-30 3.71 -7.36 5.06 5.48
2016-06-30 4.11 -6.11 4.90 5.14
2016-03-31 4.19 -5.23 4.59 4.66
2015-12-31 4.27 -4.34 4.27 4.18
2015-09-30 3.68 -4.20 3.71 4.03
2015-06-30 3.08 -4.05 3.14 3.88
2015-03-31 3.97 -3.11 2.87 4.09
2014-12-31 4.85 -2.16 2.60 4.29
2014-09-30 5.34 -1.15 2.26 4.15
2014-06-30 5.83 -0.15 1.92 4.01
2014-03-31 4.92 -0.61 1.72 3.71
2013-12-31 4.02 -1.07 1.52 3.42
2012-12-31 4.14 -1.89 1.72 4.09

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Genomic Vision Société Anonyme has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Genomic Vision Société Anonyme has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Genomic Vision Société Anonyme improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Genomic Vision Société Anonyme's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Genomic Vision Société Anonyme has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

G09 Health

 How is Genomic Vision Société Anonyme's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Genomic Vision Société Anonyme's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Genomic Vision Société Anonyme is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Genomic Vision Société Anonyme's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Genomic Vision Société Anonyme's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 27.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Genomic Vision Société Anonyme Company Filings, last reported 3 months ago.

DB:G09 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31
2018-09-30 3.20 0.17 1.02
2018-06-30 3.20 0.17 1.02
2018-03-31 3.20 0.17 1.02
2017-12-31 3.76 0.93 2.03
2017-09-30 3.76 0.93 2.03
2017-06-30 5.70 0.45 2.90
2017-03-31 5.70 0.45 2.90
2016-12-31 10.04 0.00 6.89
2016-09-30 10.04 0.00 6.89
2016-06-30 14.38 0.01 10.96
2016-03-31 14.38 0.01 10.96
2015-12-31 18.38 0.02 15.59
2015-09-30 18.38 0.02 15.59
2015-06-30 20.62 0.60 18.73
2015-03-31 20.62 0.60 18.73
2014-12-31 22.70 0.79 22.76
2014-09-30 22.70 0.79 22.76
2014-06-30 24.65 0.81 25.75
2014-03-31 24.65 0.81 25.75
2013-12-31 0.98 0.82 3.23
2012-12-31 -0.13 0.99 1.19
  • Genomic Vision Société Anonyme's level of debt (5.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (122.6% vs 5.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Genomic Vision Société Anonyme has less than a year of cash runway based on current free cash flow.
  • Genomic Vision Société Anonyme has less than a year of cash runway if free cash flow continues to reduce at historical rates of -3.1% each year.
X
Financial health checks
We assess Genomic Vision Société Anonyme's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Genomic Vision Société Anonyme has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

G09 Dividends

 What is Genomic Vision Société Anonyme's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Genomic Vision Société Anonyme dividends.
If you bought €2,000 of Genomic Vision Société Anonyme shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Genomic Vision Société Anonyme's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Genomic Vision Société Anonyme's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:G09 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:G09 Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Genomic Vision Société Anonyme has not reported any payouts.
  • Unable to verify if Genomic Vision Société Anonyme's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Genomic Vision Société Anonyme's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Genomic Vision Société Anonyme has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Genomic Vision Société Anonyme's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Genomic Vision Société Anonyme afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Genomic Vision Société Anonyme has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

G09 Management

 What is the CEO of Genomic Vision Société Anonyme's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Aaron Bensimon
COMPENSATION €266,668
TENURE AS CEO 12.9 years
CEO Bio

Mr. Aaron Bensimon, Ph.D., Co-Founded Genomic Vision, S.A in 2004 and also has been its Chief Executive Officer and president since May 2006. Mr. Bensimon serves as the Scientific Director at Genomic Vision, S.A. and served as its Chief Scientific Officer. He directed the Laboratory of Genomic Stability at the Pasteur Institute for 10 years. He is a co-inventor of the Molecular Combing Technology used by GENOMIC VISION. He has been the Chairman of the Management Board at Genomic Vision, S.A. He served as the Chairman of Supervisory Board at Genomic Vision, S.A. He is a leading international research scientist. Mr. Bensimon obtained a Ph.D. degree in Molecular Biology.

CEO Compensation
  • Aaron's compensation has been consistent with company performance over the past year.
  • Aaron's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Genomic Vision Société Anonyme management team in years:

2.2
Average Tenure
  • The tenure for the Genomic Vision Société Anonyme management team is about average.
Management Team

Aaron Bensimon

TITLE
Co-Founder
COMPENSATION
€267K
TENURE
12.9 yrs

Stéphane Altaba

TITLE
Vice President of Corporate Development & Member of Management Board
COMPENSATION
€205K
AGE
52
TENURE
2.3 yrs

Stuart Edelstein

TITLE
Co-Founder & President of Scientific Advisory Board
TENURE
15.3 yrs

Frederic Tarbouriech

TITLE
Chief Financial Officer
TENURE
2.1 yrs

Peter Coudenys

TITLE
Director of Sales & Marketing
TENURE
1.3 yrs

Sophie Gauthier

TITLE
Human Resources Director
TENURE
1.7 yrs
Board of Directors

Isabelle Racamier

TITLE
President of the Supervisory Board
COMPENSATION
€4K
TENURE
1.3 yrs

Elisabeth Ourliac

TITLE
Vice-President of Supervisory Board
COMPENSATION
€8K
TENURE
2.4 yrs

Stuart Edelstein

TITLE
Co-Founder & President of Scientific Advisory Board

Stéphane Verdood

TITLE
Member of Supervisory Board

Pierre Chagvardief

TITLE
Member of Scientific Advisory Board

Anne Dejean

TITLE
Member of Scientific Advisory Board

Nicolas Levy

TITLE
Member of Scientific Advisory Board

Daniel Louvard

TITLE
Member of Scientific Advisory Board

André Tartar

TITLE
Member of Scientific Advisory Board

Felix Mitelman

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Genomic Vision Société Anonyme's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Genomic Vision Société Anonyme has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

G09 News

Simply Wall St News

G09 Company Info

Description

Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. It offers molecular combing system (MCS), an automated instrument that stretches single DNA molecules onto vinyl silane treated glass carriers; FiberVision, an automated fluorescence microscope for high-throughput image acquisition; software solutions for the detection, measurement, and interpretation of hybridization signals on combed DNA in a streamlined and informatics process; DNA extraction kits for molecular combing applications; and accessories, such as custom treated glass carriers and disposable DNA reservoirs for use with the MCS, as well as sample cartridges for scanners. The company also provides CombHeliX FSHD probes for the diagnosis of facioscapulohumeral dystrophy; FiberProbes for BRCA that is a set of Genomic Morse Codes for the detection of mutations occurring in hereditary breast and ovarian cancer; and hereditary nonpolyposis colorectal cancer Genomic Morse Code sets, which allows the identification and characterization of various structural variations, including anomalies occurring in flanking regions of the MMR genes. In addition, it offers combing services that allow customers to validate the planned gene editing events; detect incorrect events larger than 1kb, including incorrect deletions, insertions, or inversions; and quantify off-target/on-target ratios. The company has a strategic alliance with Quest Diagnostics; research and development agreement with the Pasteur Institute; and development agreement with Integrated Technologies Ltd for the design and development of a high-throughput scanning instrument for molecular combing assays. Genomic Vision Société Anonyme was founded in 2004 and is headquartered in Bagneux, France.

Details
Name: Genomic Vision Société Anonyme
G09
Exchange: DB
Founded: 2004
€5,070,318
16,651,291
Website: http://www.genomicvision.com
Address: Genomic Vision Société Anonyme
Green Square Batiment E,
80-84 rue des Meuniers,
Bagneux,
Ile-de-France, 92220,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA GV Common Shares Euronext Paris FR EUR 02. Apr 2014
DB G09 Common Shares Deutsche Boerse AG DE EUR 02. Apr 2014
LSE 0QT4 Common Shares London Stock Exchange GB EUR 02. Apr 2014
Number of employees
Current staff
Staff numbers
45
Genomic Vision Société Anonyme employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:08
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/01
Last earnings filing: 2019/03/06
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.